Concepta announced Thursday that it has received Ethics Committee approval to commence the user trial for its myLotus product in the UK.
Concepta, the UK healthcare company with a primary focus on women's fertility, said the trial is expected to commence in the next month, with 120 women testing the device for ease of use and clarity of instructions.
Concepta has engaged the renowned UK-based company, The Clinical Trial Company, which specialises in clinical studies for pharmaceutical, biotechnology and medical device companies to manage the trial, which will be conducted in Rhyl, UK.
Erik Henau, CEO of Concepta said: 'We are delighted to announce this important milestone. Over the last few months, we have dedicated considerable effort to meet the necessary requirements and regulations in order to expedite our CE-marking process.'
'We look forward to obtaining this key certification in the coming months, which will allow us to launch our myLotus product in our initial target European markets of the UK, and subsequently, other EU markets as the Company grows.'
At 10:13am: (LON:CPT) Concepta Plc Ord 2.5p share price was +0.2p at 6.65p